By Donna Loyle, communications specialist, LIMR
Researchers seek to understand how well circulating tumor DNA (ctDNA) testing in the blood works in predicting appropriate treatment options for patients with stage IIA colon cancer after surgery. Testing for ctDNA levels may help identify patients who do and do not benefit from chemotherapy.
Participants are randomized into two study groups. One group undergoes active surveillance, which is the current standard of care for resected stage IIA colon cancer.
Those in the other cohort are split into two groups: Those in whom ctDNA has been detected in their blood undergo a chemotherapy regimen; those in whom ctDNA is not detected undergo active surveillance.
The primary objectives of this trial are to compare the rate of ctDNA clearance and recurrence-free survival in ctDNA-detected patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer.
Study #NRG-GI-005 is approved for all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email firstname.lastname@example.org or visit www.mainlinehealth.org/research/clinical-trials/nrg-gi005